Medtronic Increases Lead In Afib Market Following Gem III AT Approval
This article was originally published in The Gray Sheet
Executive Summary
Medtronic says its Gem III AT dual-chamber implantable cardioverter defibrillator (ICD), approved by FDA via PMA supplement Feb. 13, represents a more compact and powerful alternative to the company's Jewel AF for patients also at risk of atrial tachyarrhythmias. The firm began shipments immediately.